Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-021-01238-2

Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact of erenumab on acute medication usage and health care resource utilization (HCRU) among migraine patients.